CordenPharma Signs Multi-Year Agreement for the Manufacturing of a Commercial Peptide

10 January, 2023
Press Release > CordenPharma Signs Multi-Year Agreement for the Manufacturing of a Large-Volume Commercial Peptide

CordenPharma Signs Multi-Year Agreement for the Manufacturing of a Commercial Peptide

Press Release > CordenPharma Signs Multi-Year Agreement for the Manufacturing of a Commercial Peptide

[Photo by CordenPharma] Commercial Peptide Manufacturing at CordenPharma Colorado (US).

10 January 2023 – Luxembourg >

CordenPharma is pleased to announce the signing of a multi-year agreement commencing in 2023 for the contract manufacturing of a large-volume peptide at its CordenPharma Colorado facility.

The manufacturing agreement will potentially cover a value of ca. USD 1 billion, depending on actual production over the term of the agreement, and will support the launch of an innovative peptide. The companies have agreed not to disclose additional details and respect customer confidentiality.

Dr Michael Quirmbach, CEO & President of CordenPharma, commented: “We are very excited about the trust our customer has placed in CordenPharma, and are pleased to continue supporting the commercial manufacturing of this innovative peptide at our CordenPharma Colorado (US) site, which is perfectly equipped for producing these types of complex molecules.

As part of our commitment, we plan to further expand both our large and medium-scale peptide manufacturing capacity at our Colorado and Frankfurt sites, making CordenPharma the leading peptide manufacturing CDMO with full drug product integration, possible via our aseptic fill and finish capabilities in CordenPharma Caponago.”

In parallel, CordenPharma is pursuing a large investment program across its global facility network to expand capacities and technologies in key areas such as Peptides, Lipids, and Injectables, with an overall planned investment of > €200M in 2023.

Read Press Release Pdf

About CordenPharma

CordenPharma is a full-service partner in the Contract Development & Manufacturing (CDMO) of innovative APIs, Lipid Excipients, and Drug Products. Through a growing network of cGMP facilities across Europe and the US organized under five Technology Platforms – Peptides – Lipids & Carbohydrates – Injectables – Highly Potent & Oncology – Small Molecules – CordenPharma experts translate complex processes and projects at any stage of development into high-value products.

CordenPharma Media Contacts

North America
Email: abby.thompson@cordenpharma.com
Europe & Asia
Email: eva.schaub@cordenpharma.com

Name	_ga
Provider	google-analytics.com
Purpose	This cookie name is associated with Google Universal Analytics - which is a significant update to Google's more commonly used analytics service. This cookie is used to distinguish unique users by assigning a randomly generated number as a client identifier. It is included in each page request in a site and used to calculate visitor, session and campaign data for the sites analytics reports.
Cookie life cycle	2 years

Name	_gid
Provider	google-analytics.com
Purpose	This cookie is set by Google Analytics. It stores and update a unique value for each page visited and is used to count and track pageviews.
Cookie life cycle	1 Day

Name	collect
Provider	google-analytics.com
Purpose	"Used to send data to Google Analytics about the visitor's device and behavior. Tracks the visitor across devices and marketing channels.
Cookie life cycle	session

Name	vuid
Provider	vimeo.com
Purpose	Collects data on the user's visits to the website, such as which pages have been read. These cookies are used by the Vimeo video player on websites.
Cookie life cycle	2 years

Name	BE_CLA3
Provider	BrightEdge
Purpose	Enables data aggregation, analysis and report creation to assess marketing effectiveness and for website performance.
Cookie life cycle	37199 days

Essential

Statistics

Marketing

Name	__utmc
Provider	google-analytics.com
Purpose	This is one of the four main cookies set by the Google Analytics service which enables website owners to track visitor behaviour and measure site performance. It is not used in most sites but is set to enable interoperability with the older version of Google Analytics code known as Urchin. In this older versions this was used in combination with the __utmb cookie to identify new sessions/visits for returning visitors. When used by Google Analytics this is always a Session cookie which is destroyed when the user closes their browser. Where it is seen as a Persistent cookie it is therefore likely to be a different technology setting the cookie.
Cookie life cycle	Session

Name	__utmt
Provider	google-analytics.com
Purpose	This is one of the four main cookies set by the Google Analytics service which enables website owners to track visitor behaviour and measure site performance. This cookie determines new sessions and visits and expires after 30 minutes. The cookie is updated every time data is sent to Google Analytics. Any activity by a user within the 30 minute life span will count as a single visit, even if the user leaves and then returns to the site. A return after 30 minutes will count as a new visit, but a returning visitor.
Cookie life cycle	30 minutes

Name	Google Maps API
Provider	Google Maps
Purpose	to read user IP address.
Cookie life cycle	expires immediately

Name	GPS
Provider	Youtube
Purpose	YouTube is a Google owned platform for hosting and sharing videos. YouTube collects user data through videos embedded in websites, which is aggregated with profile data from other Google services in order to display targeted advertising to web visitors across a broad range of their own and other websites.
Cookie life cycle	session